Advanced nanobiosensors for the detection of neurovascular damage in cerebral infarction: prospects and challenges Authors: Lihong Yang, Jing Li, Jiawei Han, Yinan Qin Published: 2026 ABSTRACT AbstractCerebral infarction is the leading cause of neurological disability and mortality globally and is mainly caused by neurovascular damage and impaired cerebral blood flow. Conventional diagnostic methods for neurovascular injury often lack sensitivity, specificity, or are not able to monitor in real time, therefore, there is a need for accurate early detection to ensure optimal clinical results. The emergence of advanced nanobiosensors can serve as a tool to detect neurovascular damage associated with cerebral infarction. The nanosensors are nanoscale sensing platforms that are highly sensitive, fast and can detect stroke-related biomarkers at very low concentrations. Nanobiosensors combine nanomaterials like nanoparticles, nanowires, quantum dots, and biomimetic nanostructures to facilitate higher signal amplification and target-specific recognition of neurovascular biomarkers. This review aims to provide an overview of the recent developments in the detection of cerebral infarction using nanobiosensor-based technologies, especially their contribution to the identification of neurovascular injury. Although these developments have been made, some challenges are yet to be overcome, such as the issues of biocompatibility, large-scale reproducibility, and limited clinical validation of nanobiosensor platforms. Furthermore, they are not easily applicable in the clinic, lacking a protocol to follow and regulatory issues. The future perspectives of nanobiosensors in point-of-care diagnostics and personalized stroke management are discussed, highlighting the potential of nanobiosensors to revolutionize the diagnosis and monitoring of cerebral infarction in early stages.Keywords: Cerebral infarction, Nanobiosensors, Neurovascular biomarkers, Stroke diagnosis, Ischemic stroke Introduction Cerebral infarction and related cerebrovascular disorders are a significant underlying cause of neurological disability and death globally and are caused by intricate disturbances of cerebral blood flow and neurovascular integrity. Intracerebral hemorrhage (ICH) is a serious type of stroke in which there is bleeding into the brain tissue and high short-term mortality rates. Although ICH makes up a smaller percentage of all strokes worldwide, it is clinically important because of the severe neurological deterioration and few treatment options for it. In the last ten years, there have been significant advances in our knowledge of the clinical risk factors and pathophysiological mechanisms involved in the development of neurovascular damage in these diseases. The most common causes of spontaneous ICH are chronic arterial hypertension (CH) and cerebral amyloid angiopathy (CAA), secondary causes are vascular malformations, tumors and hemorrhagic transformation of ischemic stroke or venous thrombosis. Chronic hypertension is a major modifiable risk factor that causes structural remodeling of small cerebral vessels, which causes lipohyalinosis and weakening of the arterioles that ultimately rupture. These pathological changes mainly involve small perforating arteries of the deep brain areas, causing focal neurovascular damage and the disruption of adjacent tissues [1, 2]. Several inherited and acquired neurovascular diseases are associated with cerebral vascular fragility and hemorrhagic events in addition to hypertension. Neurovascular disease is characterized by endothelial dysfunction, disruption of cell-cell junctions, and increased vascular permeability which is called cavernous angioma disease. Protein mutations that alter the regulation of vascular stability and tight junctions result in altered neurovascular unit architecture, which in turn contributes to lesion formation and hemorrhage [3]. Likewise, in Moyamoya disease, the progressive occlusion of arteries is associated with the development of unusual collateral vessels as a result of the smooth muscle hyperplasia and degeneration of the arterial wall. Structural anomalies, such as arteriovenous malformations and aneurysms, are other examples of abnormalities which compromise vascular integrity and render cerebral vessels vulnerable to rupture and neurovascular injury [4, 5]. Pathological processes after intracerebral bleeding are interrelated and develop the mechanism of neurovascular injury. Initial damage is through the effects of the mass due to the formation of hematoma which causes increased ICP, midline shift, and compression of vital brain structures. This primary injury is also complicated by secondary mechanisms in the long run worsening tissue damage, causing perihematomal edema, inflammation, oxidative stress and disruption of the blood-brain barrier (BBB). Together, all these processes can disrupt the cerebral homeostasis and lead to progressive neurologic decline [6]. PHE occurs via early vasogenic pathways and subsequent inflammatory pathways that include activation of thrombin, infiltration of immune cells, and breakdown of the BBB by MMPs. Once the erythrocytes are broken open, the released hemoglobin and iron continue to cause oxidative damage, neuronal damage and cell death. Recent studies have pointed to ferroptosis, an iron-dependent regulated cell death, as an important mechanism of neurovascular and parenchymal injury [7]. The interlinkage of these pathways highlights the complexity of neurovascular damage and the need to recognize and monitor its occurrence early. The BBB is critical to cerebral homeostasis and is very important in cerebral infarction and hemorrhagic injury. The BBB is structurally organized as a highly selective barrier, including tightly connected brain microvascular endothelial cells, continuous basement membrane and astrocytic end-feet that prevent the transport of molecules. After a neurovascular injury, disruption of tight junctions and endothelial dysfunction increases [8]. In this review, the mechanisms of neurovascular damage and BBB disruption in cerebral infarction and the recent advancement of nanobiosensor based strategies for early detection are discussed, and the major prospects and challenges for clinical translation are emphasized. Types of strokes and their neurovascular impact A stroke is a sudden loss of blood supply to the brain and leads to injury to the brain cells and long-term damage to the brain. The ability of a neuron to regenerate in the damaged areas is limited, so it is difficult to get better and often recovery is incomplete. Restriction of both angiogenesis and nerve growth after ischemia plays a role in the development of infarcted brain tissue, and recovering the integrity of the neurovascular system is difficult. Research indicates that about 87% of strokes are due to blockage of blood vessels (ischemic), and the other 13% are caused by ruptured blood vessels (hemorrhagic) [9]. Ischemic stroke is caused by a blockage of a blood vessel to the brain, usually from a blood clot or embolus, that results in an inadequate supply of oxygen and nutrients to the brain. This results in the rapid death of neurons in the ischemic core area and in the penumbra area of the stroke, there are cells that are at risk but might be salvaged if the cells receive timely intervention. Common risk factors are atherosclerosis, atrial fibrillation and carotid artery disease. A haemorrhagic stroke, in contrast, is caused by a burst blood vessel in the brain which permits blood to leak into or close to the brain. The extravasated blood leads to elevated ICP, mechanical injury to neurons and derangements of normal brain function [10]. Whatever the type of stroke, the disruption of normal blood flow triggers a series of pathological events. During ischemic strokes, a lack of oxygen and glucose results in energy failure, excitotoxicity, and calcium-mediated neuronal death. Mechanical injury caused by hematoma, elevated ICP, and inflammation in the area of a hemorrhagic stroke cause further injury. The neurological deficits that occur are variable, depending on the regions of the brain affected, and impaired muscle function or paralysis on one side of the body, language impairment and disturbances in speech, vision, and cognitive function are common. The location and severity of these impairments can often be important clues to the extent and site of neurovascular damage, important for diagnosis and monitoring [11]. Biomarkers for cerebral infarction Biomarkers are measurable markers of biological processes, pathological changes or therapeutic responses. They are of key importance in stroke, and sometimes images are not very clear. The ideal cerebral infarction marker should be readily detectable, able to distinguish between ischemic and hemorrhagic stroke, reflect the early pathological change and help to make prognosis and therapeutic decisions. Their effectiveness, however, may be affected by the BBB which can affect the relationship between the level of the biomarker and the severity of the infarct [12, 13]. Lipoprotein-associated phospholipase A2 (Lp-PLA2) Lp-PLA2 is an enzyme that is primarily made by inflammatory blood vessels cells and is involved in the production of molecules that help cause inflammation. As far as stroke is concerned, high levels of Lp-PLA2 correlate with atherosclerosis and higher risk of ischemic events. It is found in the blood as a sign of current vascular inflammation and has been associated with an increased risk of stroke in the long term, particularly in those with vascular risk factors. It is even approved by the FDA for the evaluation of stroke risk, thus showing its clinical relevance [14]. S100 β protein S100 β is a protein that is found in high concentration in the supportive glial cells of the brain (astrocytes). Damage to neurons or astrocytes during stroke results in the leakage of S100 β into the cerebrospinal fluid (CSF) and later the blood. It increases rapidly following injury, which makes it a good sensitive indicator of BBB dysfunction. Intriguingly, CSF contains much higher levels of the protein than serum, and levels in serum are not affected by hemolytic samples, which makes it useful for clinical testing [15]. Matrix metalloproteinases (MMPs) The MMPs, especially MMP-2 and MMP-9, are enzymes that degrade the extracellular matrix and play a major role in remodeling brain tissue following stroke. Their activity is essential for various processes such as angiogenesis and tissue repair, but too much MMP activity early on in the recovery process can be damaging. During ischemic stroke, MMPs are responsible for the leakiness of the BBB, which further damages brain tissue. MMPs may be highest at the end, but the disruption of BBB may be happening in the beginning, and so therapeutic targeting of these enzymes may be beneficial but it is all about timing [16]. Glial fibrillary acidic protein (GFAP) GFAP is a structural protein that is only present in astrocytes. This is because when these cells are damaged, GFAP is released into the blood stream. Known as a blood marker of astrocytic damage, an elevated level of GFAP can be clinically helpful in distinguishing stroke from other forms of brain damage. It is usually elevated after days, due to continuing tissue damage and inflammation following stroke [17]. Methylarginines (ADMA/SDMA) The modified amino acids known as methylarginines disrupt nitric oxide production, an important molecule that promotes healthy blood vessels. Increased blood levels of ADMA are a sign of endothelial dysfunction and can exacerbate ischemic injury and stroke. These biomarkers are particularly useful for evaluation of vascular health and early endothelial stress [18]. MicroRNAs (miRNAs) MicroRNAs are small pieces of RNA which play a role in the regulation of gene expression and cell to cell communication. The specific miRNAs appear in the blood after the stroke, indicating neuronal damage and systemic immune processes. For instance, there are some miRNAs that control inflammation, and others that inhibit neuronal cell death. Their fast dynamic changes following ischemia render them as potential early time markers for stroke diagnosis and prognosis [19]. Aquaporin-4 (AQP4) Aquaporin-4 is a water channel protein that is mainly expressed at the end-feet of astrocytes around blood vessels. It regulates the flow of water in the brain and is important in the development of edema following stroke. There is a correlation of different AQP4 expression with cytotoxic and vasogenic brain swelling, making it a good marker for stroke severity and monitoring the response to treatment [20]. von Willebrand factor (vWF) vWF is a protein that is secreted by endothelial cells and platelets and plays a role in blood clotting and the inflammation of the blood vessels. Following ischemic stroke, vWF levels are elevated in blood indicating endothelial activation and damage. vWF is also an important vascular marker, as high levels have been linked with the risk of stroke as well as the severity of ischemic injury [21]. Interleukins (IL-4, IL-10) Interleukins are signaling molecules that control inflammation. Anti-inflammatory interleukins (IL-4 and IL-10) act to preserve brain tissue during stroke. IL-4 activates M2 microglia that aids in repair, and IL-10 inhibits the production of harmful proinflammatory cytokines. These interleukins are neuroprotective, and their elevated levels are associated with decreased tissue injury and better neurological outcomes in ischemia [22]. Endothelial and BBB biomarkers BBB integrity is very important in stroke. Caveolin-1 plays a role in the regulation of vesicle-mediated transport across endothelial cells and can serve as an early sign of BBB leakage. Early targeting of actin depolymerising factors (ADF/cofilin) that stabilize the endothelial cytoskeleton preserves the integrity of the junctions and limits BBB disruption. Pericytes are versatile cells on the abluminal side of endothelial cells that regulate barrier function as well as secrete protective growth factors such as VEGFA, PDGF-β and NGF. They can clear away debris from the cells and even participate in the repair of neurovascular. However, when stressed, they are able to generate ROS which leads to damage [23]. Inflammatory biomarkers Inflammation is a contributing factor in the process of stroke and is a result of stroke. Endothelial cells, microglia and infiltrating neutrophils release cytokines such as IL-1β, IL-6, and TNF-α, which affect the integrity of the BBB by modulating the function of junctions and cytoskeleton. During reperfusion, neutrophils exacerbate damage by releasing MMPs, elastase and ROS, and also physically blocking capillaries. There are two phenotypes of microglia and macrophages; M1 is inflammatory and injurious, whereas M2 is repair and angiogenic. This ratio of immune cells may be responsible for the severity of damage or healing [24]. Additional biomarkers from NVU studies Other molecules like tight junction proteins (occludin, claudin, ZO-1), adhesion molecules (ICAM-1, VCAM-1, selectins) and neuroprotective factors (NGF, NT3, VEGF) play an important part in stroke pathogenesis as well. Their level is indicative of BBB integrity, immune cell infiltration and reparative processes. The monitoring of these biomarkers can help to achieve a comprehensive picture of the injury of the neurovascular structures and the response of the brain after ischemia [25]. Neuron-specific enolase (NSE) Neuron specific enolase (NSE) is a glycolytic enzyme found in neurons and neuroendocrine cells and rises in serum levels when there is ischemic damage to the neurons. Its levels are associated with size of infarcts and the severity of strokes. Here high serum NSE level is linked to poor functional outcomes, and thus it is a useful prognostic biomarker despite the variability in the timing of peak. Tumor necrosis factor-alpha (TNF-α) Tumor necrosis factor-alpha (TNF-alpha) is a pro-inflammatory cytokine that is released by activated microglia and macrophages in the event of cerebral infarction. It leads to neuroinflammation, disruption of the blood-brain barrier and development of ischemic damage. High TNF-a levels are associated with the high volume of the infarct and the low neurological outcome which has highlighted its prognostic relevance in stroke. C-reactive protein (CRP) The role played by C-reactive protein (CRP) is encountered in the case of cerebral infarction. High levels of CRP reflect vascular damage, tissue injury and are associated with more severe infarcts, and worse outcomes. It has been extensively applied in risk stratification and prognosis of acute ischemic stroke patients. Correlation between clinical biomarker levels and nanobiosensor detection limits To determine the clinical utility of nanobiosensors, there is a need to match the detection limits of the nanobiosensors with the concentrations of the physiologically relevant biomarkers. Key stroke biomarkers including GFAP, NSE and S100β are generally found in blood and cerebrospinal fluid and in the range of ng/mL to pg/mL which is comparable to the detection limits of various nanobiosensor platforms. This correspondence suggests that most nanobiosensors have sufficient analytical sensitivity to be used to detect biomarkers in real-world conditions, although the variability in the expression of biomarkers and the complexity of samples can affect real-world performance. Moreover, Table 1 summarizes typical nanobiosensor platforms and key analytical performance parameters that include limit of detection, and detection time. Though not uniformly reported across all studies, the data given are a comparative overview of recent advances and their possible applicability to clinical use. Table 1Comparative overview of stroke biomarkers with clinically relevant concentrations and nanobiosensor analytical performanceBiomarkerClinical Concentration Range (Early–Peak)BiofluidBest Reported LODDetection TimeBiosensor TypeNanomaterial / PlatformClinical SuitabilityReferenceGFAP< 0.1–50 ng/mLPlasma0.23 pg/mL< 15 minElectrochemical (FET)GrapheneEarly detection[26]NSE10–200 ng/mLSerum0.00016 ng/mL~ 15 minOptical (SERS-LFIA)AuNPs / Raman tagsPrognostic monitoring[27]S100β0.2–10 ng/mLPlasma0.01 pg/mLRapidOptical (SERS / Fluorescence)AuNPs / Upconversion NPsEarly detection (low specificity)[13]MMP-950–1000 ng/mLPlasma0.00020 ng/mLRapidOptical / ElectrochemicalCarbon dots / AuNPsBBB damage monitoring[28]vWF~ 1–5 µg/mLPlasma0.1 ng/mLN/AN/AN/AEndothelial marker[29]miRNA (miR-124, miR-21)1–100 fMPlasmaLimited dataN/AElectrochemical / OpticalGraphene / QDsEmerging biomarker[30]IL-65–100 pg/mLCSF/Plasma1.63 pg/mL~ 30 minElectrochemical immunosensorAuNPs / Carbon nanomaterialsInflammation monitoring[31]IL-105–50 pg/mLPlasmaNot well establishedN/AN/AN/AAnti-inflammatory marker[31] Comparative overview of stroke biomarkers with clinically relevant concentrations and nanobiosensor analytical performance Limitations of current diagnostic techniques Although strokes are readily managed, diagnosis is still difficult and early if left untreated. The current diagnostic technologies like computed (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) have been extremely useful, but also have their limitations that impact patient care, particularly in resource poor environments. These limitations show the need for alternative diagnostic methods such as molecular markers for stroke diagnosis and mobile devices that enable earlier detection. MRI, CT, and PET limitations CT is a simple, widely available and very sensitive technique for the diagnosis of intracerebral hemorrhage (ICH), and intraventricular hemorrhage (IVH). This is because blood is denser than the surrounding brain tissue and cerebrospinal fluid, allowing hemorrhages to be easily seen. In addition to rapid detection of bleeding, CT may also be used to estimate the amount of ICH via the ABC method and severity of IVH which are significant factors affecting clinical outcomes [32]. Because of the early availability of the CT scan, ICH has been detected quickly after onset of symptoms, which is important as the hematomas are still expanding at this time. The likelihood of growth of haemorrhage can be predicted by radiological characteristics such as the presence of a blend pattern, an island pattern, a swirl pattern and a black hole on initial CT. In addition, specific patient characteristics (age, gender, hypertension, or coagulation problems) and CT findings contribute to the secondary ICH score which helps to assess the clinical usefulness of further contrast enhanced imaging. Smaller features like the “spot sign” (which signifies active bleeding) and secondary causes of ICH, including an aneurysm or arteriovenous malformation, can be detected with contrast enhanced CT and CT angiography [33]. On the other hand, MRI is superior at imaging the evolution of hematoma over time and is excellent at detecting underlying pathologies that may be missed on CT scans, such as tumor, arterial or venous infarct, and angiographically occult vascular malformations. MRI can also aid in the grading of the related ischemic cerebrovascular disease and newer sequences such as gradient echo and susceptibility imaging can identify cerebral microbleeds (CMBs) [34]. While CT and MRI are sophisticated tools, neither is capable of detecting molecular or cellular level brain damage in real-time, an important aspect for early intervention [35]. Portable diagnostic devices and biomarker panels could change the stroke care landscape by enabling first responders to identify ischemic or hemorrhagic strokes in the field. Technology could drastically shorten the time to assessment, allowing for quicker thrombolytic or endovascular treatment and drastically reduce brain damage. CT and MRI machines can be expensive and often lack expertise to make them available in resource-poor areas, which means many stroke patients can go undiagnosed and untreated. If affordable, readily available diagnostic equipment could be developed for such localities, treatment time and outcomes would be improved and quality of life for stroke survivors would be enhanced [36]. Currently, there are many different analyses used in the clinical and research environment for the identification of ischemic stroke markers. All of these methods have varying sensitivity, specificity, throughput, cost, and clinical applications. A comparative review of these techniques suggests the benefits and drawbacks of each technique in stroke diagnosis and assessment of prognosis [12, 37]. Enzyme-linked immunosorbent assay One of the most commonly used methods for quantitative detection of protein biomarkers in biological fluids is enzyme linked to immunosorbent assay (ELISA). This approach is based on the specific antigen-antibody interactions with enzyme labeled antibodies for the detection and quantification of target proteins. Many biomarkers have been measured using ELISA which have been related to stroke, such as C-reactive protein, interleukin-6, tumor necrosis factor-alpha, intercellular adhesion molecule-1, matrix metalloproteinase-9, vascular cell adhesion molecule-1, glial fibrillary acidic protein and S100 proteins. The technique is highly sensitive, highly specific, highly reproducible, and can be used to process more than one sample at a time. But the relatively longer times of assay and higher operational costs are significant drawbacks, especially in the acute clinical context [38]. Quantitative real-time polymerase chain reaction Quantitative real-time PCR is a strong molecular biology technique that can be used for measuring the level of expression of RNA by measuring the fluorescence emitted during the real time PCR amplification. This approach is especially applicable to uncovering the genetic signatures including microRNAs and long non-coding RNAs that serve as critical signaling molecules in the physiology of ischemic stroke. The advantage of qPCR is that it is very sensitive and highly specific and can quantify RNA at very low levels. Despite these advantages, the method demands good quality RNA samples, complex experimental procedures and relatively high costs, and may not be routinely used in the clinic [39]. Liquid chromatography-mass spectrometry Liquid chromatography-tandem mass spectrometry (LC-MS) is a combination of liquid chromatography and mass spectrometry. This technique has been widely used to identify metabolic biomarkers, such as fatty acid derivatives, amino acids, and oxidative stress markers such as 3-nitrotyrosine-nitrated fibrinogen, 8-iso-prostaglandin F2α and malondialdehyde. LC-MS/MS is a tool in stroke metabolomics research that offers high sensitivity, excellent specificity and multiplexed quantification. But the instrumentation is expensive, the operation is complex and it needs technical skills to use the instrumentation which hinders its use in many clinical laboratories [40]. Immunoturbidimetry Immunoturbidimetry is derived from turbidity changes which occur when the antigen and antibody form a complex in solution. Immunoturbidimetry is used for the fast and easy detection of blood coagulation and fibrinolytic parameters, such as D-dimer, fibrinogen, thrombin-antithrombin complex, tissue plasminogen activator-inhibitor complex, activated partial thromboplastin time, prothrombin time, fibrin degradation products, and serum amyloid A, which are useful in routine clinical practice and are relatively inexpensive. However, its sensitivity and specificity are generally less than more advanced analytical methods [41]. Next-generation sequencing Next generation sequencing (NGS) is a high throughput technology which allows for detailed analysis of genomic, transcriptomic and epigenomic landscapes. NGS can be used to identify DNA methylation patterns, gene expression profiles, and complex gene regulatory networks involved in the progression of the disease in stroke research. Technology offers the best throughput, sensitivity, and specificity with the ability to analyse thousands of genes and regulatory elements simultaneously. Although NGS is very powerful in the analytical ability, there is a limit on the cost of the equipment and its operation, the complexity of the data to interpret and the requirement of specialized bioinformatics expertise [42]. Single-molecule array With its ultra-high sensitivity and specificity, single molecule array (SIMOA) technology is an important breakthrough in the field of biomarker detection. SIMOA combines single-molecule technology of immunocapture with fluorescence-based detection to capture and measure biomarkers at femtomolar levels, much lower than the sensitivity of traditional ELISA. This technology allows detection of markers of neuronal injury, which are found in blood and are released in the blood more quickly after brain tissue damage, such as glial fibrillary acidic protein, neurofilament light chain and S100 proteins [43]. More recently, SIMOA has been developed to use multiplex platforms to detect more than one inflammatory or neuronal injury biomarker at the same time, thus increasing the detection efficiency and reliability of the data. NF-L has been shown to correlate with the extent of axonal damage and ultimate infarct size in patients with acute ischemic stroke. Similarly, the dynamic monitoring of the release of GFAP during the hyperacute phase of stroke is highly specific in the early detection of stroke, when evaluated with time-based sampling protocols [44]. Advances in acute ischemic stroke treatment and clot analysis Acute ischemic stroke (AIS) treatment has made tremendous progress in recent years, especially with regard to neurointervention. Rapid Mechanical Thrombectomy (MT) device design advancements have been made in the light of increased understanding of clot characteristics, and MT has become a gold standard treatment. AIS clots are extremely heterogeneous, with different sizes, colours, composition and mechanical properties that affect the successful removal of the thrombus. Other factors may affect the structure of the clot, including the cause of the stroke and previous treatment with a thrombolytic agent [45, 46]. Rationale for nanobiosensor-based detection Strokes are medical emergencies and proper brain imaging is critical to rapidly identify the area of the stroke. Micro- and nano-CT imaging techniques have recently demonstrated their potential to address these challenges. These techniques have been shown to give very detailed imaging of the cerebral vasculature in studies performed in animal models including permanent MCA occlusion in rats. Further, nanocarrier-based CT contrast agents, including PEGylated BaHoF5 nanoprobes, have been created to specifically target pathological areas of the brain. These agents offer better local imaging properties, lower doses of contrast and lower risk of complications, and thus enhance the accuracy of the diagnosis, and could alter the current paradigm for stroke detection [47, 48]. Nanotechnology-enhanced MRI for stroke MRI is a versatile tool for the diagnosis, treatment and therapeutic outcomes of strokes. Nanomaterials have been shown to be a potent tool to improve targeting and imaging. In fact, PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) have been employed to dynamically image both blood-brain barrier disruption and ischemic lesion, which can be valuable for simultaneous evaluation of both these important features. The excellent MRI properties and biocompatibility of BSA-MnO2 nanoparticles (NPs) has allowed the imaging of blood-brain barrier permeability following stroke in the experimental model at the right time [49]. Other innovations involve the development of nanoparticles of MnCO3@BSA-ICG which can enhance both MR imaging and PA imaging in infarcted areas very quickly, allowing for very precise diagnosis of acute ischemic stroke [50]. Likewise, Fe3O4 nanoparticles coated with self-peptides can enhance vascular contrast and prolong circulation time thus facilitating the accurate delineation of infarct cores, collateral vessels and ischemic penumbra. Multifunctional magnetic nanoparticles and dual-target probes further improve MRI sensitivity, allowing detection of newly formed collateral vessels and inflammatory lesions, as well as potential hemorrhagic sites [51]. Platelet membrane-coated magnetic nanoparticles loaded with L-arginine and γ-Fe2O3 can target damaged vessels, outline vascular injuries, and even induce vasodilation to limit lesion expansion, showing the therapeutic as well as diagnostic potential of nanotechnology-enhanced MRI [52]. Magnetic Particle Imaging (MPI) has been successfully tested in animal models and shows performance comparable to MRI. A notable advantage of MPI is the potential for portable, pre-hospital imaging devices. By enabling faster detection and assessment, MPI could significantly improve treatment times and patient outcomes [53]. Nanosensors integrate molecular or atomic-level sensing elements with physical transducers. These sensors utilize nanostructured components, such as carbon nanotubes, graphene, nanowires, or nanoparticles, due to their high surface area-to-volume ratio and superior sensitivity (Fig. 1). They are capable of transducing the events of binding or chemistry at the nanostructured surface to a measurable signal such as electrical, optical, thermal or electrochemical [54]. Nanosensors can be used in a variety of areas, from diagnosis and detection of diseases, food inspection, air and water purification to security and defense. They are cost-effective, have low sample volume requirement and have the potential to be integrated into portable systems [55, 56]. Various types of the nanomaterials used for cerebral stroke diagnosis. Adapted from reference [57] under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/) Use of nanosensors for detection of stroke biomarkers There are different types of nanosensors used for the detection of biomarkers including optical sensors (based on fluorescent, chemiluminescent, or plasmonic properties of the nanosensor), electrochemical sensors (that are sensitive to the electrical signal of the biomarker), photoelectrochemical sensors (combining photochemical and electrochemical mechanisms), and surface plasmon resonance (SPR) based sensors (that are sensitive to the change in refractive index of the nanosensor) and field-effect transistor (FET) based sensors (that are sensitive to the modulation of electrical signals of the nanosensor) (Fig. 2) [58]. Enhanced imaging, real-time neural cell tracking and vascular monitoring have been explored with the use of gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs) and quantum dots. Nanosheet biosensors, which are coated with nanotags that boost Raman scattering, also help to improve detection of stroke-related biomarkers, and nanowire biosensors detect biomolecular interactions through changes in conductivity. Surface-Enhanced Raman Scattering (SERS) nanotags have been applied to detect biomarkers such as matrix metalloproteinases, which are elevated during ischemic stroke [27, 59]. A schematic representation of the BBB on a chip platforms incorporating commonly used and emerging integrated or modular biosensors. Electrical measurements, such as transendothelial electrical resistance (TEER) and impedance spectroscopy are obtained using on chip sensors while electrochemical biosensors as modular units. The optical monitoring is primarily achieved through direct microscopic observation whereas the evanescent field based techniques, including surface plasmon resonance and integrated optical interferometry as external modules for the bioparticle detection. Adapted from reference [60] under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/) Electrochemical nanobiosensors use an electroactive surface enhanced with nanomaterials such as metal nanoparticles, graphene, or carbon nanotubes. A biological probe is attached to the surface and is capable of reacting with the target, producing an electrical signal. As the concentration of the analyte changes, these signals can be measured as changes in current, voltage, impedance or conductivity (Fig. 3) [61]. Nanobiosensing platforms for detection of stroke biomarkers: (A) Electrochemical sensing using electrodes modified with nanomaterials. (B) Optical platforms based on fluorescence and SERS. (C) Magnetic nanoparticles for the separation and signal transduction of biomarkers. (D) Mass detection by measuring frequency change using piezoelectric effect. (E) Heat change based on calorimetric sensing in biochemical reactions Optical nanobiosensors are based on light detection techniques like absorption, luminescence, Raman spectroscopy, surface plasmon resonance, or refractive index changes. Molecules can be recognized using nanomaterials such as gold or silver nanoparticles, graphene and quantum dots, which serve as transducers to convert the molecular recognition event into an optical measurement. Specificity for the target biomarker can be achieved by functionalization with antibodies, aptamers or enzymes [62]. Piezoelectric nanobiosensors are devices which convert the mechanical change (mass, pressure, strain etc.) to electrical signals by the Piezoelectric effect. Instead of plain metal electrodes, electrodes containing nanomaterials such as gold nanoparticles or carbon nanotubes, which increase sensitivity. The interaction between the receptor and analyte generates detectable electrical potentials that are related to the concentration of the analyte [63]. Magnetic nanobiosensors are composed of magnetic nanoparticles with biorecognition elements functionalized on them, including iron oxide or ferrites. Formation of a complex between the nanoparticle and the target analyte alters magnetic properties such as relaxation time or resonance frequency, which can be detected using techniques like magnetoresistance, magnetic particle spectroscopy, or nuclear magnetic resonance [64]. Thermal or calorimetric nanobiosensors exploit the high thermal conductivity of nanomaterials, including graphene, gold nanoparticles, and carbon nanotubes, to detect heat changes from biochemical reactions. Temperature changes or heat flow are measured to determine analyte concentration. The optimal choice of nanobiosensor depends on the target biomarker and required sensitivity. Combining different nanomaterials and sensing mechanisms can further enhance performance, providing tailored solutions for accurate disease diagnosis [65]. Nano–bio interface effects and signal variability in physiological environments Performance of the nanobiosensors is greatly affected by nano- bio interface effects and complex matrix induced variability in physiological environments. The formation of protein corona around nanoparticle surfaces can alter the accessibility of biorecognition elements, reducing the binding affinity and target specificity, and increasing the background signals and decreasing the detectability in the analysis. Moreover, the electrostatic interactions can be dampened by ionic screening in high ionic strength media such as blood and cerebrospinal fluid, which is undesirable since it leads to reduced signal transduction efficiency. In addition to interfacial effects, biological matrices add additional variability of signal by heterogeneous composition, electrochemical noise, pH variations, and electrode degradation due to biofouling. Quantitatively, a number of studies have reported the attenuation of signals in the range of 20–60% in complex biological fluids with respect to buffer systems. To cope with these issues, several mitigation methods have been used, such as antifouling surface modification (e.g., PEGylation and zwitterionic coating), selective biorecognition layer, matrix-matched calibration and signal normalization methods. Regardless of these developments, real-world inter-sample variability of nanobiosensors is one of the key translational constraints to nanobiosensor application [66, 67]. Lipid nanoparticles They are the lipid forms where the amphiphilic phospholipids and cholesterol molecules self assemble in an aqueous media and they can be used as versatile pharmaceutical carriers with their characteristics being able to be varied depending on the way of preparation, surface charge and size. Stability and blood circulation time can be enhanced by modifying the surface with polyethylene glycol (PEG) chains. Moreover, liposomes can efficiently carry DNA and protein molecules with such modifications. They are biocompatible and are suitable to encapsulate hydrophilic compounds in the aqueous core and to integrate hydrophobic molecules into the lipid bilayer, thus making them an ideal platform for controlled drug delivery and improved pharmacokinetics [68]. The different toxicities of the nanoparticles are discussed in Table 2. Table 2The toxicity profiles of different nanoparticlesNanoparticles (NPs)Reported ToxicityReferenceLiposomesShow dose-dependent genotoxic effects, mainly in lung and spleen tissues.[75]Polymeric NPs (PNPs)May induce immune responses, generate ROS in a dose-dependent manner, and present biodegradation-related concerns.[76]MicellesGenerally low genotoxicity; however, poorly designed polymers may cause oxidative stress and localized inflammation at high doses. PEGylation helps reduce toxicity.[77]Solid Lipid NPs (SLNPs)High concentrations can lead to lipid peroxidation, oxidative stress, and inflammatory responses.[78]NanoemulsionsToxicity depends on particle size, surface charge, and emulsifier type, with increased ROS.[79]NanogelsToxicity arises from residual monomers and reactive components, which may cause aggregation-related inflammation or immune activation.[80]DendrimersPositively charged forms disrupt cell membranes, induce ROS production, and exhibit limited biodegradability at higher generations.[81]Nanostructured Lipid Carriers (NLCs)Typically exhibit low toxicity, though excessive doses may cause oxidative stress and inflammation.[82]SPIONsIron release can result in oxidative stress, DNA damage, and inflammatory reactions due to iron overload.[83]Quantum DotsToxicity mainly results from degradation of surface coatings, leading to release of heavy metal cores such as cadmium.[84]Gold NPs (AuNPs)Can induce free radical–mediated cytotoxicity and potential immune-related adverse effects.[85]Carbon Nanotubes (CNTs)Fiber-like morphology contributes to cytotoxicity, DNA damage, chronic inflammation, and lung fibrosis at high doses.[86]Silver NPs (AgNPs)Linked to BBB disruption, neuronal damage, oxidative stress, and mitochondrial dysfunction due to silver ion release.[87] The toxicity profiles of different nanoparticles Polymeric nanoparticles Polymeric nanoparticles are colloidal particles (with diameters smaller than 1 μm) that are usually categorized into nanocapsules and nanospheres according to the structure. These nanoparticles are made of biocompatible polymers in aqueous solutions. Drugs are encapsulated in a cavity formed by the liquid core of nanocapsules and can be either oil or water, while nanospheres are composed of a solid polymeric matrix in which the drug is distributed throughout the matrix [69]. Quantum dots The quantum dots (QDs) are nanometric semiconductor particles, usually a few nanometers in size, which exhibit quantum mechanical properties. It imparts them special properties in the optical and electronic domain such as tunable light emission, high brightness and photostability. By altering the size and form of QDs, it is possible to control the colour and optical properties of them. They are structurally made of a semiconducting core (CdTe, CdSe etc.) and covered by a shell of material (ZnS etc.) that increases surface area and quantum efficiency. Their imaging properties are outstanding, however, they are toxic for use in vivo due to the presence of heavy metal such as cadmium, lead or arsenic [70]. Silicon nanoparticles While quantum dots have many desirable properties, silicon nanoparticles are not only environment-friendly, but they are also biocompatible. If smaller than 10 nm, they have high quantum yields and broad visible spectrum emission which makes them effective fluorescent detectors for bioimaging. Comparing silicon nanoparticles to cadmium containing QDs, in vivo studies show that silicon nanoparticles break down into silicic acid and can be excreted via the urinary system. Their excellent fluorescent properties, low toxicity and biodegradability make them promising for biomedical imaging and diagnosis [71]. Dendrimers Dendrimers are highly branched, tree-like, macromolecules made up of natural or synthetic materials. They have a central core, inner branching junctions and outer branched surface, which offer uniformity, defined size and water solubility. Surface functional groups on the dendrimer can be used for covalent or electrostatic binding of drugs, imaging agents or other biomolecules, turning dendrimer molecules into special-purpose carriers. Therapeutic molecules can also be encapsulated by hydrophobic interactions or hydrogen bonding in the internal cavities. The biocompatibility and the fact that they can pass through the kidneys without biodegradation makes dendrimers excellent vehicles for targeted drug delivery [72]. Carbon nanoparticles Nanoparticles with carbon include spherical fullerenes and cylindrical fullerenes known as carbon nanotubes (CNTs). CNTs are tubes made up of rolled up sheets of graphite with typical diameters of 1 nm and lengths of 1–100 nm; fullerenes are hollow spheres with diameters of 1–2 nm for monostructures and tens of nanometers for polystructures. These structures are able to be internalized into cells through endocytosis, and their mechanical integrity, chemical stability and large surface area are suitable for drug delivery and imaging. Fullerenes and CNTs are produced by combustion or melting: their special form and dimension allow for various biomedical applications [73]. Metal-based nanoparticles In the biomedical field, metal based nanoparticles, such as AuNPs and iron oxide nanoparticles are broadly used. AuNPs are chemically stable, controllable in size and shape and can change their optical properties depending on their morphology. Normally, iron oxide nanoparticles, including magnetite, maghemite, and hematite, are synthesized by alkaline co-immersion of iron ions in water in the presence of hydrophilic polymers such as PEG, which results in the formation of small hexagonal crystals with the size of 3–5 nm. Magnetic fields are used to direct these particles, allowing for targeted delivery and imaging in vivo. These types of metal-based nanoparticles have good stability combined with fair biocompatibility, which are crucial for developing nanotechnology-based biosensing and therapeutic approaches [74]. Biorecognition elements Antibodies For their high specificity and high binding capacity to target antigens, antibodies have long been considered as the gold standard and have been extensively used in many functional and analytical applications. They can specifically identify biomolecules, and are very useful for biosensing, diagnostics and therapeutic platforms. But, antibodies have a number of intrinsic limitations. Natural antibody based recognition systems can have low chemical and thermal stability and short shelf life, and can be costly and complex to modify. Their use is limited due to such challenges, especially when it comes to harsh environmental or industrial conditions [88]. In response to these disadvantages, many efforts have been made to develop alternatives to antibodies. Biomimetic recognition elements have been developed and are being introduced as alternatives, and offer higher robustness, selectivity and limit of detection. Among these options, molecularly imprinted polymers and aptamers have attracted a lot of attention with the ability to bind to the antigen similar to the antibody, but with greater stability and flexibility. These synthetic systems offer good recognition performance and their design can be customized for particular analytical and sensing applications [89]. Molecularly imprinted polymers are synthetic polymers that contain selective recognition sites resembling the target molecule in structure and chemical properties. The imprinted cavities of these polymers bind the target analyte in a selective, high affinity fashion like biological receptors. Molecularly imprinted polymers are considered as artificial antibodies because of their high specificity. They have a high chemical stability and a great tolerance to harsh environmental conditions and can be designed in a flexible way, which makes them very well suited in various biochemical sensing applications. In the process of synthesis the target molecule serves as a template and recognition sites are formed that are able to recall the target after it is eliminated. These polymers have binding properties similar to natural antibodies and have been proven to perform very well in biosensing, separation, catalysis, and drug delivery [90]. Aptamers One of the most promising alternatives to antibodies for molecular recognition technologies is aptamers (Fig. 4). Most often, they are short strands of nucleic acid, either DNA or RNA, but sometimes they are small peptides. Aptamers have been called chemical antibodies because they have a high binding affinity to their target molecules, especially proteins. Aptamers are completely chemically synthesized and selected in vitro by the systematic evolution of ligands by exponential enrichment process, which is different from antibodies. This is one of the high throughput selection methods that makes it possible to isolate aptamers of high affinity and specificity to target of interest [91]. Unlike antibodies, another major benefit of aptamers is that they are sequences of well-defined molecules and can be easily chemically synthesized without batch to batch variations, and the synthesized aptamers can be reproduced. These benefits make aptamers appealing for a variety of applications that have been the realm of antibodies. Aptamers have been investigated as imaging agents, sensors, diagnostic agents, drug delivery agents, therapeutic agents, theranostic systems and analytical platforms. Although aptamer technology has great potential, it is much less developed than antibody-based technology systems and there are still some obstacles to overcome, including aptamer specificity and crossreactivity in complex biological environments [92]. Besides aptamers, several other antibody substituents have been developed. The affibodies are modified, engineered protein scaffolds that comprise a three-helix structure for target recognition coupled to a bacterial IgG-binding protein. RGD peptides contain a sequence of the three amino acids Arg-Gly-Asp, and are cyclic peptides with a high binding affinity for integrins present in the extracellular matrix that are widely used in drug delivery and imaging. Small organic molecules have also been used as targeting ligands; especially in the field of cancer, where folate receptors are over-expressed [93]. A schematic illustration of various types of the biological recognition elements [95] Enzymes and molecularly imprinted polymers (MIPs) MIPs are polymeric matrices that are able to selectively recognize and bind target molecules at the molecular level. The molecular imprinting technique consists of polymerisation of functional monomers in the presence of a target molecule that acts as a template for polymerisation. After removal of the template, the obtained polymer has the same size, shape, and chemical functions as the target molecule in the binding sites. The affinity and selectivity of these binding sites is similar to antibody-antigen interactions [94]. Novel nanodrug delivery systems for stroke therapy A major stroke therapy challenge is to deliver drugs to the ischemic brain regions in an accurate manner, and to overcome the BBB. Many drugs do not enter into brain parenchyma, due to its highly selective BBB. But, nanocarriers overcome this restriction by allowing precise engineering, such as modification of the surface with ligands like conjugation or size optimization, to cross the BBB and to deliver drugs specifically to ischemic areas. Nanocarriers can be engineered to allow for controlled and sustained release over a prolonged period of time to ischemic tissue for neuroprotection, neuroregeneration, and functional recovery [96]. Targeted thrombolytic nanocarriers for stroke therapy Various approaches have been developed to improve targeted and enhanced thrombolysis with nanomedicines such as biomimetic, ligand mediated and physical stimuli. Physical approaches involve the use of external forces including ultrasound, magnetic fields, shear stress and light to improve drug delivery and therapeutic effects. Acoustic waves can be used to induce microbubble oscillation and apply mechanical forces to break up thrombi in ultrasound-mediated thrombolysis. Furthermore, ultrasound has the potential to destabilise drug-loaded microbubbles, which releases the drugs locally to increase the local drug concentration. The MNPs with superparamagnetic iron oxide cores can be used for site-specific delivery and enhance the thrombolytic efficacy when magnetically guided [97]. MNPs have been modified by enzyme conjugations (nattokinase, lumbrokinase) and surface coatings including poly(lactic acid)-poly(ethylene glycol), cationic pH-sensitive polyelectrolytes, carboxymethyl dextran, carboxymethyl chitosan and sodium alginate. For instance, chitosan-coated, drug-loaded MNPs retained its thrombolytic activity and site-specific retention at lower doses without inducing any hepatic or renal toxicity [98]. A nanomotor was developed in 2024 by suitably encapsulating in a nanovesicle (liposome) iron oxide, perfluorohexane, and urokinase. It was shown to have increased thrombus penetration when guided by magnetic field and triggered by near-infrared and ultrasound stimuli [98]. Shear responsive nanoparticles have also been investigated in the treatment of thrombosis, and are termed shear-deformable NPs or shear-dissociated NP aggregates. The deformable nanoparticles are able to change their shape for site-specific drug delivery without generation of byproducts, while the shear-sensitive NP aggregates disassemble under shear stress to release their payload directly at the thrombus. Developed near-infrared light responsive liposomal gold nanorods that release urokinase-plasminogen activator (uPA) on-demand upon exposure to near-infrared light and used near-infrared light to induce uPA production in a thermo-sensitive TRPV1 (transient receptor potential vanilloid 1) synthetic signaling pathway [99]. The combination strategies have further improved thrombolysis: the erythrocyte-membrane camouflaged nanocapsules with ultra-small iron oxide particles and urokinase that exploited the dual effect of photothermal and magnetothermal, thereby increasing the effect of the clot lysis. Again, the red blood cell membrane-encapsulated MNP aggregates that synergistically integrate mechanical, photothermal, and photodynamic thrombolysis resulted in a significant decrease in the weight of the thrombus [100]. Precise site-specific targeting can be attained by using ligand mediated targeting strategies which make use of functional ligands expressed on nanocarriers. Activated platelets and fibrin are targets of ligands that are used in thrombolysis. The ligands can be peptides, antibodies, or polysaccharides, especially one called Arg-Gly-Asp (RGD). Markers like platelet glycoprotein IIb/IIIa (GP IIb/IIIa), P-selectin, factor XIII, fibrin, and fibrin-fibronectin complexes are additional markers used for targeting. Additionally, ligand-mediated approaches can be integrated with stimuli-responsive techniques, including ultrasound or magnetic field-guided nanoparticles, to enhance targeting efficiency [101]. Biomimetic nanocarriers like Platelet-derived NPs exhibit high adherence and retention at thrombus sites while releasing growth factors that assist in vascular repair. However, due to limited BBB permeability, platelet-based NPs have primarily been applied to tPA delivery. Tat peptide modifications have been used to improve BBB penetration and thus the ability to deliver drugs to specific locations. Erythrocyte membrane coated NPs are desired because they have high tensile strength and deformability, which would result in long circulation time and decreased clearance by immune cells. Various modifications, including chemical, lipid, and genetic alterations, have been used to improve drug delivery efficacy. Macrophage- and monocyte-coated NPs enhance targetability while minimizing immune response, and neutrophil membrane-coated NPs exploit neutrophil accumulation in the ischemic penumbra to improve anti-inflammatory drug delivery. Fibrin-targeted NPs have been developed to assess thrombus suitability for recanalization therapy. Dual-targeting systems recognizing both platelets and fibrin, show significantly higher clot anchorage compared to single-target systems [102]. Lipid and polymeric nanoplatforms Early polymeric nanoparticles (PNPs) employed non-biodegradable polymers such as polyacrylate, polystyrene, polyacrylamide, and poly(methyl methacrylate) (PMMA), which, despite their efficacy, posed risks of inflammatory responses. Contemporary PNPs predominantly utilize biodegradable polymers including poly(lactide-co-glycolide) (PLGA), poly(D, L-lactide) (PLA), polyalkylcyanoacrylates, polycaprolactone (PCL), and poly(D, L-glycolide) (PLG)—due to their biocompatibility, low toxicity, and regulatory approval by agencies such as the FDA and EMA. For instance, PLGA has hydrolyzable ester bonds which slowly break down, allowing for controlled drug release [103]. Studies indicate the therapeutic potential of polymeric nanoparticles in stroke treatment. The intranasal delivery of miRNA-124 with PLGA nanoparticles modified using PEG and RVG29 was successful for the reduction of ischemia-reperfusion injury [104]. Erythropoietin (EPO) encapsulated in PLGA nanoparticles coated with cholic acid (EPO-CA-NPs) exhibited increased penetration of BBB and significantly decreased infarct volume and neuronal apoptosis compared to free EPO. Likewise, polycaprolactone based-nanoparticles such as naringenin loaded gelatin-PCL nanoparticles demonstrated significant anti-inflammatory activity and human mesenchymal stem cell protection in case of oxygen-glucose deprivation [105]. There are several other polymers such as chitosan and its derivatives that have been employed for neuroprotection. Gallic acid-encapsulated carboxymethyl chitosan NPs have been able to reduce inflammatory markers like TNF-α and IL-1β, and alpha-phenyl-N-tert-butyl nitrone (α-PBN) and AKBA encapsulated in chitosan or CS-PEG nanoparticles improved antioxidant, anti-inflammatory, and neuroprotective activity through modulation of pathways including Nrf2, HO-1, NF-κB, and 5-LOX [106]. When administered intranasally, OPN peptide using gelatin nanoparticles, the infarct volume was significantly reduced. The advanced systems comprise red blood cell membrane-coated ROS-responsive core NPs loaded with stroke-homing peptides that enable precise ROS-responsive therapeutic release in ischemic tissues. Enzyme cleavable, surface-targeted delivery within the ischemic brain using block copolymer-based nanoparticles conjugated with AMD3100 molecules has been shown to be precise and efficient targeting [107]. Human serum albumin (HSA) and bovine serum albumin (BSA) are widely used as carriers in the field of drug delivery because of their biocompatibility and binding ability. HSA nanoparticles based on a nanoparticle albumin-bound (NAB) technology that enhances the solubility of CLP for intravenous administration. CLP-ANPs exhibited strong neuroprotective properties against cerebral ischemia/reperfusion in a rat model of middle cerebral artery occlusion (MCAO). Resveratrol-loaded HSA nanoparticles (Res-HSA-NPs, ~ 100 nm), administered intravenously in rats subjected to transient MCAO, enhanced neurological outcomes, reduced infarct size, mitigated neuronal apoptosis, and attenuated oxidative stress, highlighting their potent neuroprotective effects [108]. The micelles are made by spontaneous self-assembly of amphiphilic block copolymers that have hydrophobic and hydrophilic segments. Hydrophobic drugs are loaded into the core by means of hydrophobic and covalent interactions, and hydrophilic molecules such as proteins, nucleic acids and peptides can be loaded by electrostatic interactions to create polyion complex cores. Polymeric micelles have a high chemical versatility that enables control of drug release, stability and targeting to a particular organ or tissue. Reelin was packaged within PLGA-PEG micelles together with neural stem cells (NSCs) for a mouse photothrombotic stroke model, which sustained neural proliferation, neurite outgrowth and differentiation in vitro [109]. In vivo, it increased migrating neural progenitor cells (DCX+) and mature neurons (NeuN+) at the lesion site. The cRGD and triphenylphosphine (TPP)-modified PEG-acetal-PCL-PEG pH-responsive micelle system contains resveratrol. This system was able to efficiently cross the BBB by cRGD-mediated transcytosis, and was able to deliver resveratrol directly to mitochondria to lower ROS levels and shift microglial polarization from the pro-inflammatory M1 to the neuroprotective M2 phenotype [110]. PAMAM, PLL, triazine and PPI are common dendrimer types that are widely used in drug delivery, diagnostics and therapy, and second generation dendrimer-amplified albumin biopolymers loaded with citicoline have been used for evaluating permeability and therapeutic efficacy in hypoxia models. PEGylation of dendrimers extends systemic circulation time and reduces the toxicity of hypoxic conditions. Further, functionalization of dendrimers with either arginine or histidine has been successfully used for the delivery of plasmid DNA, with improved therapeutic results in stroke models [111]. Nanogels are very hydrated networks of cross-linked hydrophilic polymers, such as CONH2, SO3H and OH groups, which are able to absorb a high amount of fluid without compromising their structure. Surface functionalization through ATRP makes it possible to prepare stimuli responsive carriers for bioimaging, biosensing, tissue engineering and targeted drug delivery. The nanogels containing urokinase, made of glycol chitosan and aldehyde-capped poly(ethylene oxide), exhibited high diagnostic sensitivity and therapeutic efficacy in the acute ischemic stroke in vivo model via sonothrombolysis. Similarly, PEG-crosslinked nanogels loaded with urokinase were able to significantly decrease microthrombi formation and adverse effects as compared to free urokinase, allowing for dual targeting of large vessels and microcirculatory system [112]. The functional groups like CONH2, OH, CONH and SO3H help in the formation of hydrogel network, while the porous architecture regulates the cross-link density, porosity and diffusion of the drug in the matrix that result in the loading and release profiles. A co-delivery of stromal-derived factor-1α (SDF-1α) and basic fibroblast growth factor (bFGF) using hyaluronic acid based nanohybrid hydrogels containing sulfated glycosamine polyelectrolyte nanoparticles was effective in modulating endogenous neural stem cells and reducing infarct volume in the case of a photothrombotic ischemic stroke model [106]. To make targeted delivery, liposomes can be modified maintaining the integrity of the drugs. Liposomes loaded with borneol (BO-TA-Lip) showed a decrease in inflammatory protein expression in brain tissue and improved neurological outcomes [113]. Elastic liposomes containing carnosine (CAR-ELs) were found to be neuroprotective in a rat model of cerebral ischemia. The intraperitoneal injection of nanoliposomes containing basic fibroblast growth factor (bFGF) proved to be beneficial in reducing the cerebral ischemia-reperfusion injury and improving locomotor and neurological function. Liposomes containing Cyclosporine A (CsA) were able to suppress inflammation, as shown by the decrease in myeloperoxidase activity and the levels of TNF-α. PEGylated lipid nanoparticles (PLNs) linked to Fas ligand exhibited high brain-targeting efficiency with the major presence in the microglial cells on ischemic areas [114]. Niosomes are biodegradable, biocompatible and stable, and thus are suitable for controlled delivery of drugs. Niosomes loaded with alpha-lipoic acid (ALA) were able to reduce cerebral ischemic damage. The niosomes containing thymoquinone reduced the expression of inflammatory markers and oxidative stress. A niosomal formulation containing ascorbic acid and tocopherol showed neuroprotective effects in MCAO rat models [115]. Biodistribution of solid lipid nanoparticles (SLNs) is governed by surface characteristics, including particle size and hydrophobicity, supporting their application in brain-targeted delivery of hydrophilic therapeutics. Intranasal administration of valsartan-loaded SLNs effectively mitigated stroke-induced damage, while melatonin-loaded SLNs enhanced therapeutic efficacy and reduced cerebral injury following ischemic events [116]. Nanoemulsions (NEs) are kinetically stable colloidal systems composed of two immiscible phases, typically oil and water, stabilized by surfactants and co-surfactants, enabling efficient dispersion and enhanced delivery. Cationic nanoemulsion to deliver TNFα siRNA, effectively reducing TNFα levels in LPS-induced neuroinflammation models. Ahmad et al. developed thymoquinone-loaded mucoadhesive nanoemulsions (TNME) via ionic gelation. Intranasal administration of TNME improved TQ bioavailability and locomotor activity in MCAO stroke models compared to intravenous delivery bypassing the BBB [117]. Bioinspired nanocarriers Exosomes are generated through endosomal pathways and are capable of targeted delivery due to their natural membrane interactions. Curcumin-loaded embryonic stem cell–derived exosomes (MSEC-exoCur) attenuated infarct size, neurological deficits, edema, and inflammation while promoting vascular integrity. Edaravone-loaded macrophage-derived exosomes (Edv-Exo) decreased neuronal death and modulated microglial polarization. Astrocyte-derived exosomes (AS-Exo) inhibited apoptosis and suppressed pro-inflammatory cytokine expression in oxygen–glucose deprivation models [118]. Baicalin-loaded macrophage-derived exosomes (Exo-BA) enhanced solubility, brain targeting, and neuroprotection in transient and permanent MCAO models. c(RGDyK)-modified MSC-derived exosomes carrying curcumin (cRGD-Exo-Cur) effectively reduced inflammation and apoptosis compared to free curcumin [119]. Inorganic / imaging-enabled theranostic nanomaterials Carbon-based nanomaterials materials exist in diverse allotropic forms. Their unique physicochemical properties make them promising candidates for drug delivery, biosensing, and neuroprotective applications [120]. Carbon nanotubes (CNTs) exist as single-walled (SWCNTs) or multi-walled (MWCNTs) structures. Single-walled carbon nanotubes (SWCNTs) are composed of seamless graphene cylinders, whereas multi-walled carbon nanotubes (MWCNTs) comprise multiple concentric graphitic layers. Amine-functionalized MWCNTs have been employed for nerve growth factor (NGF) delivery, resulting in reduced cytotoxicity and enhanced activity of ROS-scavenging enzymes. Similarly, PEGylated MWCNTs loaded with dexamethasone exhibited improved thermal stability and attenuated cytotoxic effects in PC12 cells. In addition, nickel hydroxide–MWCNT composite systems have enabled real-time glucose sensing under oxidative stress conditions in neural cell models [121]. The most popular form, C60, is composed of 60 carbon atoms in a highly symmetrical cage of 12 pentagons and 20 hexagons known as fullerenes or buckyballs. They have special sp2 hybridized carbon that gives them exceptional chemical and physical properties. The biomedical applications of fullerenes can be expanded by chemical modification with hydrophilic groups like carboxylic acids, polyhydroxyls (fullerenols), amino acids or amphiphilic polymers, as demonstrated by the mitigation of oxidative stress and modulation of aquaporin-1 expression in ischemic stroke models by fullerenol nanoparticles [122]. Nanodiamonds (NDs) are a mixed carbon structure with both graphitic (sp2) and diamond-like (sp3) bonding, they are polyhedral with 14 facets, 36 edges and 24 vertices. These are produced by detonating carbon containing explosives (detonation NDs) or by high pressure, high temperature (HPHT) grinding of microdiamond powders. NDs can also be functionalized on the surface so that drugs and biologically active molecules can be covalently attached to them, enabling targeted drug delivery [123]. Drugs, peptides, antibody and imaging agents are attached to the graphene oxide (GO) surfaces through functionalization. For instance, ruthenium carbonyl clusters anchored on GO can oxidize to RuO2, releasing CO to exert its blood vessel vasodilation effect in cortical photothrombotic ischemia models. Similarly, nanocomposites of reduced GO with gold oxide (rGO/Au2O3) have been developed for neural probes, enabling rapid detection of H2O2 in vitro and precise in vivo monitoring of oxidative stress in stroke models [124]. MNPs with surface modification, such as PEGylation, prolongs circulation and reduces nonspecific uptake, making them suitable for drug delivery, imaging, and biosensing applications. Among MNPs, iron oxide nanoparticles (IONPs) including magnetite (Fe3O4), maghemite (γ-Fe2O3), and hematite (MFe2O4) exhibit superparamagnetism, enabling aggregation under a magnetic field and dispersion when the field is removed. IONPs in MRI, CT, PET, NIRF imaging, and biosensors. For instance, PLGA- and L-carnosine-functionalized Fe3O4 nanoparticles loaded with dexamethasone have shown efficient BBB-targeted drug delivery in ischemic stroke therapy [125]. Selenium nanoparticles (SeNPs) are of growing interest due to selenium’s role in antioxidant defense, neurogenesis, redox regulation, and mitochondrial function. Zero-valent SeNPs exhibit enhanced biocompatibility, bioavailability, and neuroprotective effects. PEGylated SeNPs conjugated with anti-transferrin antibodies (OX26) have demonstrated neuroprotection by modulating inflammatory and metabolic pathways. Similarly, Se@SiO2 reduces oxidative stress, apoptosis, and BBB permeability in intracerebral hemorrhage models, and Se-taxifolin nanocomplexes show potent antioxidative effects, during ischemia/reperfusion [126]. AuNPs functionalized with Dictyopteris divaricata extract have been reported to regulate apoptotic signaling by upregulating the anti-apoptotic protein Bcl-2 while downregulating cleaved caspase-3, caspase-9, p53, p21, and Bax expression. They also reduce oxidative stress and apoptosis in ischemic models while activating protective signaling pathways such as Akt [127]. Platinum nanoparticles (Pt NPs) exhibit potent catalytic activity toward scavenging of reactive oxygen species (ROS), including superoxide anions and hydrogen peroxide, thereby functionally emulating antioxidant behavior of enzymes such as superoxide dismutase, catalase, and peroxidase. In vitro studies demonstrated that Pt NPs reduce intracellular O₂ levels and prevent ROS-induced cell death in HeLa cells. In ischemic stroke models, administration of Pt NPs decreased ROS generation in brain tissue, reduced infarct volume, and improved neurological function. They also prevent early disruption of the neurovascular unit by suppressing matrix metalloproteinase-9 (MMP-9), thereby protecting the brain’s structural integrity [128]. Polymer-functionalized mesoporous silica nanoparticles (MSNs), such as lactoferrin-conjugated hollow mesoporous manganese-doped silica nanoparticles (LHMMSNs), facilitate the translocation of resveratrol across the blood–brain barrier, enabling targeted delivery to sites of neuroinflammation. Studies revealed that LHMMSN enhanced antioxidant enzyme activity, increased anti-inflammatory cytokine IL-10 and anti-apoptotic Bcl-2, while reducing pro-inflammatory markers (TNF-α, IL-1β, IL-6) and apoptotic proteins (BAX, cleaved caspase-3), demonstrating their neuroprotective efficacy [129]. CeO2 NPs are potent scavengers of ROS due to transition ability (Ce3+ to Ce4+). Surface modifications with targeting ligands and polymers further enhance their therapeutic potential. For instance, Angiopep-II and PEGylated CeO2 nanoparticles containing endothelin-1 receptor antagonists can cross the BBB via receptor mediated transcytosis, and together decrease oxidative stress. Further, the pep-fuco functionalised MnO2 nanoparticles also have thrombolytic activity and are able to target and release urokinase locally to control the inflammatory microenvironment, making it a potential therapeutic agent for ischemic stroke [130]. Preclinical & clinical advancements The first work on sonothrombolysis involved the application of ultrasound along with conventional thrombolysis in order to create cavitation and increase the flow of fluid within the thrombi. A groundbreaking clinical trial was performed on patients with acute ischemic stroke due to middle cerebral artery occlusion, and studied the impact of high frequency transcranial Doppler ultrasound therapy as an adjunct to intravenous tissue plasminogen activating [131]. Early recanalization and clinical improvement were significantly higher in the ultrasound-treated group, but long-term outcome revealed only a non-significant trend. Later smaller trials and meta-analyses showed improved early recanalization, but were inconsistent in their findings of functional improvement after three months. A subsequent large-scale, randomized controlled trial was stopped early for futility reasons although no increase in symptomatic intracerebral hemorrhage was observed. However, a smaller patient population has been linked to an increased hemorrhagic risk with low-frequency ultrasound exposure and in combination with thrombolytic therapy [132, 133]. However, encouraging preclinical data prompted a phase Ib/II safety trial of dodecafluoropentane emulsion in patients with acute ischemic stroke, which was randomized, placebo controlled, and double blind. They were given multiple doses over the course of 12 h from the onset of symptoms; there were no significant differences in adverse events compared with placebo. Interestingly, there was a correlation between higher dose and better functional outcome at 1 and 3 months on the modified Rankin scale [134]. At the same time, the new treatment, microbubble-assisted sonothrombolysis was introduced. It was thought that the microbubbles might serve as cavitation nuclei, lowering the energy necessary to achieve good disruption of the thrombus. Clinical trials showed that treatment with microbubbles and ultrasound and thrombolytic therapy led to better early recanalization. The field is consistently developing, with current phase 2 clinical trials testing new nanoemulsion-based treatments for large-vessel occlusion stroke and other PFC compounds [135]. An active field of investigation is the use of nanoparticles for diagnosis. Macrophages have been seen to infiltrate in unique ways in the early ischemic stages, which may indicate potential for personalized anti-inflammatory treatments. Despite the premature termination of certain clinical trials examining inflammation imaging with nanoparticles, these studies highlighted how nanotechnology could be used in the diagnosis of stroke [136]. However, transient MCAO is not a model of clinical large-vessel occlusion strokes for which very few patients have a good chance of recanalization. The increase in the use of thrombus-based in vivo models, including the photothrombotic stroke and the thrombin injection models, would support patient pathophysiology [137]. Molecular targets beyond simply dissolving a thrombus, with an emphasis on stability of the endothelial cell. An important advantage of the use of nanoparticles-based platforms is the ability to provide co-delivery of thrombolytic agents and endothelial-protective molecules, which will help in minimizing secondary damage and optimizing therapeutic benefits [138]. Integration with microfluidics and lab-on-a-chip systems The use of sensors and biosensors in organ on a chip platforms to measure metabolic activity has been growing rapidly, and different operating principles are being used, such as amperometry, potentiometry, electrochemistry, and optical sensing. These systems facilitate the real-time monitoring of important physiological parameters like oxygen levels, pH of culture medium, concentration of metabolites (such as glucose and lactate) and detection of particular biomarkers or pathogens. However, the use of sensing technologies in the BBB-on-a-chip (BBBoC) devices is still limited, mostly for spatial reasons. In order to overcome these challenges, both the on-chip integrated and externally modular configuration of the sensor have been suggested for BBBoC applications [139]. Clinical translation and regulatory challenges The advantages of using nanoparticles in biomedical applications are enormous; however, safety and toxicity issues are major challenges that researchers and regulatory authorities face. There is experimental evidence that some nanoparticles are able to activate innate immune sensing pathways. Silicon dioxide, silver nanoparticles, titanium dioxide and aluminium oxide are materials that have been demonstrated to induce immune responses. These nanoparticles can trigger the inflammasome pathways by binding to leucine-rich repeat-containing family members, pyrin domain-containing protein 3 and nucleotide-binding domains, which could modify immune cell subsets such as decreasing white blood cell counts and increasing neutrophil subsets. Immune-related effects have important safety implications, especially for repeated or prolonged exposure [140]. Besides their biological activity, nanomaterials also have specific physicochemical properties that make them difficult to characterize and to reproduce and standardize. They have complex interactions with biological systems, due to their size, surface charge, morphology, and functionalization. Therefore the physicochemical characteristics, biocompatibility and toxicological profile of these devices must be well documented to be assessed by the regulatory authorities such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Nanomaterials are more complex than conventional pharmaceuticals and may require regulatory evaluation in ways that go beyond what is currently in place for pharmaceuticals [141]. There are a number of nanotechnology-based products that have been FDA approved for use in disease treatments especially cancer, but the regulatory structures are still in development to address the unaddressed issues of scalability, long-term safety and efficacy. The absence of uniform experimental procedures hampers the comparison of results between different studies and a uniform line in the regulatory domain. To address this shortage, international organisations such as the International Electrotechnical Commission (IEC) and the International Standards Organisation (ISO) are developing consensus on the design, evaluation and application of nanotechnology related products to diagnose and treat stroke [106]. Surface coating of nanoparticles with polyethylene glycol or dextran has been suggested as a feasible way of reducing toxicity-related concerns. Such changes can help to enhance biocompatibility, decrease immune recognition, and increase the circulation time. However, it is important to select the right nanoparticles for particular biomedical use and assess their safety at each step of development. In addition, questions about long-term safety, bioaccumulation, and environmental effects pose further ethical and societal issues for clinical use of nanotechnology. To ensure public trust and acceptance of nanotechnology in medicine, there must be transparency in communication, both about its benefits and about its risks. It is therefore imperative to include ethics and public views in the regulation decision-making process. Furthermore, implementing safe production methods and creating environmentally friendly or biodegradable nanomaterials will play a crucial role in reducing the environmental footprint and fostering the sustainable progress of nanomedicine. In addition to safety and toxicity issues, a number of technical and translational challenges exist for the clinical use of nanobiosensors for stroke diagnostics at the point of care. They are the absence of standardization of the assays, poor inter-laboratory reproducibility, production challenges at large scale and instability of operation in real world conditions. Further, the integration into easy-to-use and transportable diagnostics packages and seamless incorporation into clinical workflows is not yet realized. To bridge the gap between prototype development in the laboratory and clinically approved point-of-care diagnostic devices, it is important to align to regulatory requirements, particularly those set by the U.S. Food and Drug Administration, as well as to benchmark the device’s performance across multiple centers in clinical trials and to ensure the performance is standardized [142, 143]. Furthermore, there is a well-defined regulatory pathway for the introduction of nanobiosensors into clinical use, based on in vitro diagnostics and medical devices. This is typically started with preclinical validation (analytical performance validation, sensitivity, specificity, limit of detection and biocompatibility testing). This is then preceded by clinical validation by using multi-phase studies to show diagnostic accuracy using actual patient samples. Then regulatory submissions will have to be made and quality management system, manufacturing standards and risk classification requirements will need to be met. The U.S. Food and Drug Administration (FDA) uses its clearance pathway and/or approval process such as the 510(k) pathway or De Novo classification and/or Premarket Approval (PMA) for approval of pathways in the United States based on the risk level of a device. In the CE marking regulations the EMA is structured in a similar way. The significance of early adoption of these regulatory requirements from the developers of such devices is crucial and will ensure smooth clinical translation of nanobiosensor-based point-of-care diagnostics [144]. Conclusion Stroke is a severe healthcare crisis that is caused by a disruption of blood supply to certain regions of the brain resulting in a damage or even death of the neurons. It is important to act quickly as the delays may be associated with worsening clinical outcomes and permanent neurological impairment or death. Acute loss in the barrier function is a pathological problem and a special promise of new therapeutic and diagnostic delivery strategies are needed. Some of the unique physicochemical properties of nanomaterials are used to cross the BBB and deliver therapeutic and theranostic agents to the ischemic brain, overcoming a few drawbacks of the traditional methods. The possibilities of nanotechnology in various areas of stroke management such as thrombolysis, neuroprotection and neuronal repair are also significant. Moreover, the nanotheranostic platforms can offer the ability to early detect stroke and the ability to monitor response to treatment, in real time, that can be integrated into more personalized and precise treatment strategy. The case of translation is different, with encouraging results found in preclinical studies with nanotechnology based systems but show limited clinical application. Some of the significant challenges include long term biocompatibility and toxicity, stability in body environments and being able to be synthesized on a large scale and approved by regulatory standards. Moreover, the intricacy of stroke pathology and a variation in how patients respond are still barriers to effective clinical translation. The development of multifunctional and biocompatible and targeted nanoplatforms with enhanced blood-brain barrier penetration efficiency and high levels of diagnostic-therapeutic integration should be further developed in the future. The use of artificial intelligence, multimodal imaging and point-of-care biosensing technologies can further benefit the early diagnosis and monitoring of treatment. Nanotechnology will be a transformational idea in terms of progressing precision medicine in the diagnosis, treatment, and real-time monitoring of diseases. Acknowledgements None. Author contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. All the authors listed meet the criteria for authorship as per the ICMJE guidelines, read the final manuscript and agree to publish this work. Funding None. Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval and consent to participate Not Applicable. This is a review paper and does not involve direct research on humans or animals. Consent for publication “Not applicable” as this manuscript does not contain data from any person. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.